Call for consistent OS reporting on drugs Overall survival (OS) results should be clearly and consistently listed on cancer drug labels, health researchers argue. A review of FDA-approved cancer drugs found “substantial variation” in OS reporting, which could hinder prescribers’ identification of clinically significant or undetermined survival benefits. OS “is arguably the most definitive patient-relevant ...
News in brief: Call for consistent OS reporting; Oncology researcher wins $3m Fellowship; Smoking associated with lower thyroid cancer risk
15 Jul 2021